Pluto Bioinformatics

GSE128056: Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer

Bulk RNA sequencing

The results from our study have identified two clinically relevant, divergent and druggable pathways (DNA repair and STAT3) that can be targeted in combination to effectively combat drug resistance. We also found that the same pathways that were deregulated in palbociclib-resistant cells were also altered in tumor samples obtained from patients who progressed while on palbociclib and endocrine therapy SOURCE: Khandan Keyomarsi (kkeyomar@mdanderson.org) - UT MD Anderson Cancer Center